Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alerni N"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Giannetti, Federica, Barbieri, Miriam, Shiti, Assad, Casini, Simona, Sager, Philip T, Das, Saumya, Pradhananga, Sabindra, Srinivasan, Dinesh, Nimani, Saranda, Alerni, Nicolò, Louradour, Julien, Mura, Manuela, Gnecchi, Massimiliano, Brink, Paul, Zehender, Manfred, Koren, Gideon, Zaza, Antonio, Crotti, Lia, Wilde, Arthur A M, Schwartz, Peter J, Remme, Carol Ann, Gepstein, Lior, Sala, Luca, Odening, Katja E
Publikováno v:
Giannetti, Federica; Barbieri, Miriam; Shiti, Assad; Casini, Simona; Sager, Philip T; Das, Saumya; Pradhananga, Sabindra; Srinivasan, Dinesh; Nimani, Saranda; Alerni, Nicolò; Louradour, Julien; Mura, Manuela; Gnecchi, Massimiliano; Brink, Paul; Zehender, Manfred; Koren, Gideon; Zaza, Antonio; Crotti, Lia; Wilde, Arthur A M; Schwartz, Peter J; ... (2023). Gene-and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2. Europace, 25(5) Oxford University Press 10.1093/europace/euad094
Aims Current long QT syndrome (LQTS) therapy, largely based on beta-blockade, does not prevent arrhythmias in all patients; therefore, novel therapies are warranted. Pharmacological inhibition of the serum/glucocorticoid-regulated kinase 1 (SGK1-Inh)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c04ac7456d2158420e5c7310d0aca50
https://boris.unibe.ch/182008/1/euad094.pdf
https://boris.unibe.ch/182008/1/euad094.pdf
Autor:
Bains S; Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic and The Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905, USA., Giammarino L; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Nimani S; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Alerni N; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Tester DJ; Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic and The Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905, USA., Kim CSJ; Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic and The Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905, USA., Christoforou N; Formerly from the Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USA., Louradour J; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Horváth A; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Beslac O; Department of Cardiology, University Hospital Bern, University of Bern, Bern, Switzerland., Barbieri M; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Matas L; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Hof TS; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Lopez R; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland., Perez-Feliz S; Department of Cardiology, University Heart Center, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany., Parodi C; Experimental Surgical Facility, Experimental Animal Center, University of Bern, Bern, Switzerland., Garcia Casalta LG; Experimental Surgical Facility, Experimental Animal Center, University of Bern, Bern, Switzerland., Jurgensen J; Department of Virology & Gene Therapy, Vector and Vaccine Engineering Laboratory, Mayo Clinic, Rochester, USA., Barry MA; Department of Virology & Gene Therapy, Vector and Vaccine Engineering Laboratory, Mayo Clinic, Rochester, USA., Bego M; Formerly from Biomedicine Design, Pfizer Inc., Cambridge, MA, USA., Keyes L; Formerly from Biomedicine Design, Pfizer Inc., Cambridge, MA, USA., Owens J; Formerly from the Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USA., Pinkstaff J; Drug Safety Research & Development, Pfizer Inc., Cambridge, MA, USA., Koren G; Cardiovascular Research Center, Brown University, Providence, USA., Zehender M; Department of Cardiology, University Heart Center, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany., Brunner M; Department of Cardiology, University Heart Center, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.; Department of Cardiology and Intensive Care, St. Josefskrankenhaus Freiburg, Freiburg, Germany., Casoni D; Experimental Surgical Facility, Experimental Animal Center, University of Bern, Bern, Switzerland., Praz F; Department of Cardiology, University Hospital Bern, University of Bern, Bern, Switzerland., Haeberlin A; Department of Cardiology, University Hospital Bern, University of Bern, Bern, Switzerland., Brooks G; Formerly from the Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USA., Ackerman MJ; Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic and The Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, Rochester, MN 55905, USA., Odening KE; Translational Cardiology, Department of Cardiology and Department of Physiology, University Hospital Bern, University of Bern, Bühlplatz 5, 3012 Bern, Switzerland.; Department of Cardiology, University Heart Center, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.
Publikováno v:
European heart journal [Eur Heart J] 2024 Sep 29; Vol. 45 (36), pp. 3751-3763.